表紙
市場調查報告書

組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98) :開發中產品分析

Histone Deacetylase 3 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 364840
出版日期 內容資訊 英文 105 Pages
訂單完成後即時交付
價格
Back to Top
組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98) :開發中產品分析 Histone Deacetylase 3 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 105 Pages
簡介

本報告提供以組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98) 為標的之治療藥開發相關資訊,提供您開發階段,藥物標的,作用機制,給藥途徑及各分子類型分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98)概要

治療藥的開發

組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98):開發中的產品 - 各開發階段

組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98):開發中的產品 - 各治療範圍

組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98):開發中的產品 - 各適應症

組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98):企業開發中的產品

組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98):大學/機關開發中的產品

組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98):治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98)治療藥的開發企業

  • 4SC AG
  • Chipscreen Biosciences Ltd
  • Curis, Inc.
  • GlaxoSmithKline Plc
  • HitGen LTD
  • IRBM Science Park SpA
  • Merck & Co., Inc.
  • Sigma-Tau S.p.A.
  • Syndax Pharmaceuticals, Inc.
  • TetraLogic Pharmaceuticals

藥物簡介

組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98):暫停中的計劃

組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98):主要消息與新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2046TDB

Summary

According to the recently published report 'Histone Deacetylase 3 - Pipeline Review, H2 2019'; Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) pipeline Target constitutes close to 16 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Histone deacetylase 3 is an enzyme encoded by the HDAC3 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. It participates in the regulation of transcription through its binding with the zinc-finger transcription factor YY1. This protein can also down-regulate p53 function and thus modulate cell growth and apoptosis.

The report 'Histone Deacetylase 3 - Pipeline Review, H2 2019' outlays comprehensive information on the Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 4, 6 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Infectious Disease and Musculoskeletal Disorders which include indications Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lymphoma, Non-Small Cell Lung Cancer, Adenoid Cystic Carcinoma (ACC), B-Cell Non-Hodgkin Lymphoma, Breast Cancer, Burkitt Lymphoma, Epithelial Ovarian Cancer, Glioblastoma Multiforme (GBM), Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma (Kahler Disease), Mycosis Fungoides, Neuroblastoma, Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Squamous Cell Carcinoma, Triple-Negative Breast Cancer (TNBC), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Basal Cell Carcinoma (Basal Cell Epithelioma), Bone Disorders, Central Nervous System (CNS) Tumor, CNS Lymphoma, Colon Cancer, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Drug Addiction, Endometrial Cancer, Fallopian Tube Cancer, Gliosarcoma, High-Grade Glioma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Human Papillomavirus (HPV) Associated Cancer, Liver Fibrosis, Lung Adenocarcinoma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Renal Cell Carcinoma, Metastatic Uveal Melanoma, Muscle Invasive Bladder Cancer (MIBC), Myelodysplastic Syndrome, Natural Killer Cell Lymphomas, Neuroendocrine Cancer, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Parkinson's Disease, Pediatric Diffuse Intrinsic Pontine Glioma, Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Post-Traumatic Stress Disorder (PTSD), Prostate Cancer, Recurrent Medulloblastoma, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL) and Renal Cell Carcinoma.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98)
  • The report reviews Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Overview
  • Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
  • 4D Pharma Plc
  • 4SC AG
  • Chipscreen Biosciences Ltd
  • Curis Inc
  • IRBM Science Park SpA
  • Kdac Therapeutics Inc
  • Medivir AB
  • Merck & Co Inc
  • Oceanyx Pharmaceuticals Inc
  • OnKure Inc
  • Shuttle Pharmaceuticals Inc
  • Syndax Pharmaceuticals Inc
  • Zhejiang Hisun Pharmaceutical Co Ltd
  • Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Drug Profiles
  • domatinostat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • entinostat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fimepinostat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KDAC-0001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • largazole - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MRx-1299 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OKI-422 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • remetinostat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit HDAC-3 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit HDAC1, HDAC2 and HDAC3 for Burkitt Lymphoma - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SP-1161 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptide to Inhibit HDAC for Prostate Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tucidinostat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • vorinostat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Dormant Products
  • Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 06, 2019: Curis Announces Positive Safety, Tolerability and Pharmacokinetic Data in Ongoing Phase 1 Study of Fimepinostat in Combination with Venetoclax
  • Dec 02, 2019: Chidamide gets approval in China for breast cancer indication
  • Nov 06, 2019: Curis abstracts for Fimepinostat accepted for presentation at the 61st Annual Meeting of the American Society of Hematology
  • Oct 21, 2019: 4SC: Poster presentation at 1st International Symposium on Merkel Cell Carcinoma
  • Oct 16, 2019: 4SC and Netherlands Cancer Institute Collaborate on clinical evaluation of domatinostat in the neoadjuvant setting in melanoma
  • Sep 23, 2019: 4D pharma: Publication of data on neurodegenerative disease programme MRx0029
  • Aug 06, 2019: Curis provides update on development of Fimepinostat
  • Jul 25, 2019: Positive safety review of phase Ib/II EMERGE study of domatinostat + avelumab in gastrointestinal cancer
  • Jul 25, 2019: 4D pharma provides update on MRx1299
  • Jul 11, 2019: 4SC announces Positive safety review of Phase Ib/II SENSITIZE study of domatinostat + pembrolizumab in melanoma
  • May 13, 2019: Positive data from the remetinostat Phase II study in basal cell carcinoma presented at SID Annual meeting
  • May 13, 2019: 4D pharma presents on its Parkinson's Disease drug candidate MRx0029 at Neuro4D Conference, Frankfurt, Germany
  • May 07, 2019: Data From the Remetinostat Phase II Study in Basal Cell Carcinoma Patients to be Presented at the 2019 SID Annual Meeting
  • May 02, 2019: 4D to present preclinical data on MRx 0029 at Neuro4D conference
  • Apr 08, 2019: 4SC: Domatinostats mode of action in Merkel cell carcinoma
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by 4D Pharma Plc, H2 2019
  • Pipeline by 4SC AG, H2 2019
  • Pipeline by Chipscreen Biosciences Ltd, H2 2019
  • Pipeline by Curis Inc, H2 2019
  • Pipeline by IRBM Science Park SpA, H2 2019
  • Pipeline by Kdac Therapeutics Inc, H2 2019
  • Pipeline by Medivir AB, H2 2019
  • Pipeline by Merck & Co Inc, H2 2019
  • Pipeline by Oceanyx Pharmaceuticals Inc, H2 2019
  • Pipeline by OnKure Inc, H2 2019
  • Pipeline by Shuttle Pharmaceuticals Inc, H2 2019
  • Pipeline by Syndax Pharmaceuticals Inc, H2 2019
  • Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Dormant Products, H2 2019 (Contd..2), H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top